Amendment to LONG TERM MANUFACTURING AGREEMENTLong Term Manufacturing Agreement • March 7th, 2023 • Seres Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT (the “Amendment”), to that certain Long Term Manufacturing Agreement by and between Seres Therapeutics, Inc. and BacThera AG, dated as of November 8, 2021 (the “LTMA”), is made and entered into as of December 14, 2022 by and between Seres Therapeutics, Inc. (“Seres”), a corporation organized and existing under the laws of Delaware, having its principal place of business at 200 Sidney Street, Cambridge, MA 02139, USA; and BacThera AG, a joint venture between Chr. Hansen A/S and Capsugel Belgium NV, a Lonza Group Affiliate, (“Lonza”), having a place of business at Hochbergerstrasse 60A, 4057 Basel, Switzerland (“Bacthera”). Seres and Bacthera may be referred to herein individually as a “Party” or collectively as the “Parties.”
